A study to assess the pharmacokinetics and safety of tocilizumab in patients with Active Systemic Juvenile Idiopathic Arthritis.

A study to assess the pharmacokinetics and safety of tocilizumab in patients less than 2 years old with Active Systemic Juvenile Idiopathic Arthritis.

Registry ID

EUCTR2015-000435-33

Source registry

EUCTR

Phase

PHASE1

Sponsor

F. Hoffmann-La Roche Ltd

Start date

2015-06-11

Last update

2026-08-16

Conditions

• Systemic Juvenile Idiopathic Arthritis (sJIA)

Summary

To evaluate the pharmacokinetics of Tocilizumab (TCZ) over 12 weeks in patients less than 2 years of age with sJIA.

Locations

• , , Belgium
• , , Germany
• , , Hungary
• , , Spain
• , , Poland
• , , UK
• , , France

Related clinical trials

• Ilaris NIS in Korea
• Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT

View on source registry